β-synuclein aggregates and induces neurodegeneration in dopaminergic neurons

Ann Neurol. 2013 Jul;74(1):109-18. doi: 10.1002/ana.23905. Epub 2013 Aug 6.

Abstract

Objective: Whereas the contribution of α-synuclein to neurodegeneration in Parkinson disease is well accepted, the putative impact of its close homologue, β-synuclein, is enigmatic. β-Synuclein is widely expressed throughout the central nervous system, as is α-synuclein, but the physiological functions of both proteins remain unknown. Recent findings have supported the view that β-synuclein can act as an ameliorating regulator of α-synuclein-induced neurotoxicity, having neuroprotective rather than neurodegenerative capabilities, and being nonaggregating due to the absence of most of the aggregation-promoting NAC domain. However, a mutation of β-synuclein linked to dementia with Lewy bodies rendered the protein neurotoxic in transgenic mice, and fibrillation of β-synuclein has been demonstrated in vitro.

Methods: Neurotoxicity and aggregation properties of α-, β-, and γ-synuclein were comparatively elucidated in the rat nigro-striatal projection and in cultured neurons.

Results: Supporting the hypothesis that β-synuclein can act as a neurodegeneration-inducing factor, we demonstrated that wild-type β-synuclein is neurotoxic for cultured primary neurons. Furthermore, β-synuclein formed proteinase K-resistant aggregates in dopaminergic neurons in vivo, leading to pronounced and progressive neurodegeneration in rats. Expression of β-synuclein caused mitochondrial fragmentation, but this fragmentation did not render mitochondria nonfunctional in terms of ion handling and respiration even at late stages of neurodegeneration. A comparison of the neurodegenerative effects induced by α-, β-, and γ-synuclein revealed that β-synuclein was eventually as neurotoxic as α-synuclein for nigral dopaminergic neurons, whereas γ-synuclein proved to be nontoxic and had very low aggregation propensity.

Interpretation: Our results suggest that the role of β-synuclein as a putative modulator of neuropathology in aggregopathies like Parkinson disease and dementia with Lewy bodies needs to be revisited.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biophysical Phenomena / drug effects
  • Biophysical Phenomena / genetics
  • Calcium / metabolism
  • Cells, Cultured
  • Dependovirus / physiology
  • Dopaminergic Neurons / metabolism*
  • Dopaminergic Neurons / ultrastructure
  • Embryo, Mammalian
  • Female
  • Green Fluorescent Proteins / genetics
  • Green Fluorescent Proteins / metabolism
  • Membrane Potentials / drug effects
  • Microscopy, Electron, Transmission
  • Mitochondria / drug effects
  • Mitochondria / ultrastructure
  • Mutation / genetics
  • Nerve Degeneration / chemically induced*
  • Rats
  • Rats, Wistar
  • Respiration
  • Substantia Nigra / cytology
  • Transfection
  • Vesicular Monoamine Transport Proteins
  • alpha-Synuclein / genetics
  • alpha-Synuclein / toxicity
  • beta-Synuclein / genetics
  • beta-Synuclein / metabolism*
  • gamma-Synuclein / genetics
  • gamma-Synuclein / metabolism

Substances

  • Slc18a2 protein, rat
  • Vesicular Monoamine Transport Proteins
  • alpha-Synuclein
  • beta-Synuclein
  • enhanced green fluorescent protein
  • gamma-Synuclein
  • Green Fluorescent Proteins
  • Calcium